KR102341446B1 - 안구 질병을 치료하는 방법 - Google Patents

안구 질병을 치료하는 방법 Download PDF

Info

Publication number
KR102341446B1
KR102341446B1 KR1020197009679A KR20197009679A KR102341446B1 KR 102341446 B1 KR102341446 B1 KR 102341446B1 KR 1020197009679 A KR1020197009679 A KR 1020197009679A KR 20197009679 A KR20197009679 A KR 20197009679A KR 102341446 B1 KR102341446 B1 KR 102341446B1
Authority
KR
South Korea
Prior art keywords
compound
diabetic
bmx
cells
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197009679A
Other languages
English (en)
Korean (ko)
Other versions
KR20190045304A (ko
Inventor
조지 청-이 치오우
치아-난 첸
Original Assignee
네이처와이즈 바이오테크 & 메디칼스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네이처와이즈 바이오테크 & 메디칼스 코포레이션 filed Critical 네이처와이즈 바이오테크 & 메디칼스 코포레이션
Publication of KR20190045304A publication Critical patent/KR20190045304A/ko
Application granted granted Critical
Publication of KR102341446B1 publication Critical patent/KR102341446B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197009679A 2016-09-29 2017-09-29 안구 질병을 치료하는 방법 Active KR102341446B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401725P 2016-09-29 2016-09-29
US62/401,725 2016-09-29
PCT/CN2017/104345 WO2018059543A1 (en) 2016-09-29 2017-09-29 Methods for treating ocular diseases

Publications (2)

Publication Number Publication Date
KR20190045304A KR20190045304A (ko) 2019-05-02
KR102341446B1 true KR102341446B1 (ko) 2021-12-21

Family

ID=61688114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197009679A Active KR102341446B1 (ko) 2016-09-29 2017-09-29 안구 질병을 치료하는 방법

Country Status (9)

Country Link
US (1) US11045435B2 (enExample)
EP (1) EP3518913B1 (enExample)
JP (3) JP2019531296A (enExample)
KR (1) KR102341446B1 (enExample)
CN (1) CN109789115A (enExample)
CA (1) CA3038845C (enExample)
MY (1) MY198731A (enExample)
TW (1) TWI765917B (enExample)
WO (1) WO2018059543A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
BR112023024812A2 (pt) * 2021-05-28 2024-02-20 Novelwise Pharmaceutical Corp Combinação e método para tratar um câncer resistente à temozolomida, método para um tratamento pessoal de precisão para um câncer resistente a fármacos, e, uso da combinação

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011020999A (ja) 2009-04-03 2011-02-03 Genshin Seigi Yakuhin Kofun Yugenkoshi ヒストン脱アセチル化酵素を阻害するためのシナミック化合物とその誘導体
CA2946086A1 (en) * 2014-04-17 2015-10-22 Teraclon Idf, S.L. Recombinant monoclonal antibodies vnar neutralizing the vascular endothelial growth factor (vegf)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504460A1 (en) * 2002-11-12 2004-05-27 Peter G. Klimko Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP4873904B2 (ja) * 2005-08-22 2012-02-08 国立大学法人弘前大学 眼血管血流障害改善剤
US20100056522A1 (en) 2007-03-28 2010-03-04 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient
CA2630174A1 (en) * 2007-05-02 2008-11-02 Mitchell Alan Winnik Loading quantum dots into thermo-responsive microgels by reversible transfer from organic solvents to water
EP2259771A1 (en) 2008-03-03 2010-12-15 Pharmalight Inc. Stimulation of ocular retrobulbar flow using ocular irritants
PT2346827E (pt) * 2008-08-27 2014-02-17 Leo Pharma As Derivados de piridina como inibidores de receptor vegfr-2 e proteína tirosina quinase
EP2236503B1 (en) * 2009-04-03 2014-02-26 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387B1 (en) * 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
ES2820855T3 (es) * 2011-05-09 2021-04-22 Allegro Pharmaceuticals Llc Antagonistas del receptor de integrina y sus métodos de uso
US9956254B2 (en) * 2015-02-26 2018-05-01 Naturewise Biotech & Medicals Corporation Extract of taiwanese propolis for treating ocular diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011020999A (ja) 2009-04-03 2011-02-03 Genshin Seigi Yakuhin Kofun Yugenkoshi ヒストン脱アセチル化酵素を阻害するためのシナミック化合物とその誘導体
CA2946086A1 (en) * 2014-04-17 2015-10-22 Teraclon Idf, S.L. Recombinant monoclonal antibodies vnar neutralizing the vascular endothelial growth factor (vegf)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. Yang et al, PLOS ONE (2013) Vol.8, No.11, e81592
T.J. Chen et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015) Vol.36, No.3, pp.893-906

Also Published As

Publication number Publication date
MY198731A (en) 2023-09-20
WO2018059543A1 (en) 2018-04-05
EP3518913B1 (en) 2025-07-23
US20180085329A1 (en) 2018-03-29
EP3518913A4 (en) 2020-05-27
US11045435B2 (en) 2021-06-29
JP2021138710A (ja) 2021-09-16
EP3518913A1 (en) 2019-08-07
TWI765917B (zh) 2022-06-01
KR20190045304A (ko) 2019-05-02
CA3038845A1 (en) 2018-04-05
JP2023116748A (ja) 2023-08-22
JP2019531296A (ja) 2019-10-31
TW201828933A (zh) 2018-08-16
EP3518913C0 (en) 2025-07-23
CA3038845C (en) 2022-04-19
CN109789115A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
Wang et al. Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
Ko et al. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma
Chae et al. Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration in mouse models of age-related macular degeneration
Wang et al. Melatonin ameliorates oxidative stress-mediated injuries through induction of HO-1 and restores autophagic flux in dry eye
Moran et al. Protective and antioxidant effects of PPARα in the ischemic retina
Guan et al. Puerarin ameliorates retinal ganglion cell damage induced by retinal ischemia/reperfusion through inhibiting the activation of TLR4/NLRP3 inflammasome
Wang et al. Calpain-1 and calpain-2 play opposite roles in retinal ganglion cell degeneration induced by retinal ischemia/reperfusion injury
Cao et al. Protection of the retinal ganglion cells: intravitreal injection of resveratrol in mouse model of ocular hypertension
Liu et al. Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure
JP2023116748A (ja) 眼疾患の処置方法
Albalawi et al. Immunomodulatory effects of Kaempferol on microglial and Macrophage cells during the progression of diabetic retinopathy
Kyhn et al. Delayed administration of glial cell line-derived neurotrophic factor (GDNF) protects retinal ganglion cells in a pig model of acute retinal ischemia
US11707445B2 (en) Composition for blocking angiogenesis
US20140163082A1 (en) Pyrazolyl compounds for use in reversing reactive gliosis
KR102642795B1 (ko) 망막 질환을 치료하기 위한 미라베그론
MX2013011684A (es) Preparaciones oftalmicas basadas en el polipeptido activador de la adenilato ciclasa de la pituitaria que restauran la funcion visual normal en glaucoma temprano.
Chen et al. Vitamin K1 Alleviates Retinal Inflammation Following Acute Ocular Hypertension by Modulating Microglial Ferroptosis
Jia et al. Edaravone promotes motoneuron survival and functional recovery after brachial plexus root avulsion and reimplantation in rats: Involvement of SIRT1/TFEB pathway
US20210340516A1 (en) Compositions containing arginase 1 for the treatment of neurovascular and retinal vascular disorders
HK40002019A (en) Methods for treating ocular diseases
EP4138820A1 (en) Small molecules for treating age-related retinal diseases
KR102068697B1 (ko) 염증성 안구표면질환의 예방 또는 치료용 조성물
JP6386713B2 (ja) 脳循環障害の予防剤および／または治療剤
Pinal et al. Current trends in glaucoma: what about neuroprotection?

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5